We are analyzing https://link.springer.com/article/10.1007/s11033-025-10713-x.

Title:
Melatonin and necroptosis: therapeutic aspects based on cellular mechanisms | Molecular Biology Reports
Description:
Necroptosis is a regulated form of programmed cell death. It is integral to the development of various diseases, such as neurological disorders, lung injuries, liver fibrosis, and testicular toxicity. This process is orchestrated by essential molecular pathways that involve receptor-interacting protein kinases (RIP1/RIP3) and mixed lineage kinase domain-like protein (MLKL), which lead to membrane disruption, the release of damage-associated molecular patterns (DAMPs), and subsequent inflammation. Melatonin, recognized for its potent antioxidant and anti-inflammatory properties, has emerged as a promising therapeutic agent that can inhibit necroptosis through various mechanisms. In neurological diseases such as intracerebral hemorrhage, traumatic brain injury, and cerebral ischemia-reperfusion, melatonin suppresses necroptosis by downregulating RIP1/RIP3/MLKL signaling, upregulating A20 (TNFAIP3), and inhibiting the HMGB1/TLR4/NF-κB pathway. In lung disorders, melatonin attenuates cadmium- and LPS-induced necroptosis by modulating the Ang-II axis, reducing TNF-α-mediated signaling, and acting through MT1/MT2 receptors. In liver fibrosis models, melatonin inhibits RIP1-RIP3 necrosome formation, reduces oxidative stress, and decreases DAMPs-mediated immune responses. Similarly, in testicular toxicity induced by tetrabromobisphenol A (TBBPA), melatonin suppresses necroptosis by inhibiting the several pathways and reducing ROS overproduction. These findings highlight melatonin’s ability to modulate necroptosis across diverse tissues, offering protection against inflammation, oxidative stress, and cell death. By targeting necroptosis-related pathways, melatonin presents a versatile therapeutic strategy for treating diseases characterized by excessive cell death and inflammation, including stroke, myocardial infarction, pancreatitis, and autoimmune disorders. This review underscores the potential of melatonin as a novel intervention for necroptosis-related pathologies, emphasizing its role in restoring cellular homeostasis and mitigating tissue damage. Graphical Abstract
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Science

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

The income method remains a mystery to us.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, pubmed, google, scholar, melatonin, cas, necroptosis, cell, central, hosseinzadeh, death, mehrzadi, inflammation, injury, oxidative, zhang, apoptosis, signaling, sheibani, stress, therapeutic, reiter, res, molecular, diseases, pathways, cells, mol, med, liu, pathway, pineal, review, attenuates, role, biol, protective, wang, research, cancer, nature, mechanisms, receptors, potential, access, current, effects, sci, curr, pourhanifeh,

Topics {✒️}

mir-140-5p/tlr4/nf-κb axis hmgb1/tlr4/nf-κb pathway myd88/nf–κb signaling pathway pten/pi3k/akt signaling pathway suppressing hif-1α/ros/vegf receptor-interacting kinase-3-mediated pathway reducing tnf-α-mediated signaling downregulating rip1/rip3/mlkl signaling month download article/chapter high glucose-induced apoptosis ubiquitin-modifying enzyme a20 age-related macular degeneration 4-tetra-brominated diphenyl ether h2o2-dependent jnk activation age-related skin deterioration lipopolysaccharide-induced liver damage inhibits inflammasome-dependent neuroinflammation rip1/rip3 necrosome forms acute lung injury receptor signaling pathway melatonin attenuates cadmium targeting necroptosis-related pathways full article pdf cerebral ischemia-reperfusion protein-coupled melatonin receptors traumatic brain injury microrna-140-5p ameliorates receptor-interacting protein normal control subjects chronic kidney disease privacy choices/manage cookies promoting bax activation kinase ripk3 independent apoptotic pathways age-related diseases restoring cellular homeostasis oses-prieto ja chronic lung inflammation reperfusion injury keap1-independent mechanism fish kidney cells related subjects reduces oxidative stress oxidative/nitrosative stress liver fibrosis models future research directions necroptosis-related pathologies lps-induced necroptosis ang-ii axis sequential signaling complexes

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Melatonin and necroptosis: therapeutic aspects based on cellular mechanisms
         description:Necroptosis is a regulated form of programmed cell death. It is integral to the development of various diseases, such as neurological disorders, lung injuries, liver fibrosis, and testicular toxicity. This process is orchestrated by essential molecular pathways that involve receptor-interacting protein kinases (RIP1/RIP3) and mixed lineage kinase domain-like protein (MLKL), which lead to membrane disruption, the release of damage-associated molecular patterns (DAMPs), and subsequent inflammation. Melatonin, recognized for its potent antioxidant and anti-inflammatory properties, has emerged as a promising therapeutic agent that can inhibit necroptosis through various mechanisms. In neurological diseases such as intracerebral hemorrhage, traumatic brain injury, and cerebral ischemia-reperfusion, melatonin suppresses necroptosis by downregulating RIP1/RIP3/MLKL signaling, upregulating A20 (TNFAIP3), and inhibiting the HMGB1/TLR4/NF-κB pathway. In lung disorders, melatonin attenuates cadmium- and LPS-induced necroptosis by modulating the Ang-II axis, reducing TNF-α-mediated signaling, and acting through MT1/MT2 receptors. In liver fibrosis models, melatonin inhibits RIP1-RIP3 necrosome formation, reduces oxidative stress, and decreases DAMPs-mediated immune responses. Similarly, in testicular toxicity induced by tetrabromobisphenol A (TBBPA), melatonin suppresses necroptosis by inhibiting the several pathways and reducing ROS overproduction. These findings highlight melatonin’s ability to modulate necroptosis across diverse tissues, offering protection against inflammation, oxidative stress, and cell death. By targeting necroptosis-related pathways, melatonin presents a versatile therapeutic strategy for treating diseases characterized by excessive cell death and inflammation, including stroke, myocardial infarction, pancreatitis, and autoimmune disorders. This review underscores the potential of melatonin as a novel intervention for necroptosis-related pathologies, emphasizing its role in restoring cellular homeostasis and mitigating tissue damage.
         datePublished:2025-06-17T00:00:00Z
         dateModified:2025-06-17T00:00:00Z
         pageStart:1
         pageEnd:13
         sameAs:https://doi.org/10.1007/s11033-025-10713-x
         keywords:
            Melatonin
            Necroptosis
            Inflammation
            Oxidative stress
            Animal Biochemistry
            Animal Anatomy / Morphology / Histology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11033-025-10713-x/MediaObjects/11033_2025_10713_Figa_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11033-025-10713-x/MediaObjects/11033_2025_10713_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11033-025-10713-x/MediaObjects/11033_2025_10713_Fig2_HTML.png
         isPartOf:
            name:Molecular Biology Reports
            issn:
               1573-4978
               0301-4851
            volumeNumber:52
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer Netherlands
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Mohammad Sheibani
               affiliation:
                     name:Iran University of Medical Sciences
                     address:
                        name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
                        type:PostalAddress
                     type:Organization
                     name:Iran University of Medical Sciences
                     address:
                        name:Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Azam Hosseinzadeh
               affiliation:
                     name:Iran University of Medical Sciences
                     address:
                        name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Iman Fatemi
               affiliation:
                     name:Kerman University of Medical Sciences
                     address:
                        name:Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Saeed Mehrzadi
               affiliation:
                     name:Iran University of Medical Sciences
                     address:
                        name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Melatonin and necroptosis: therapeutic aspects based on cellular mechanisms
      description:Necroptosis is a regulated form of programmed cell death. It is integral to the development of various diseases, such as neurological disorders, lung injuries, liver fibrosis, and testicular toxicity. This process is orchestrated by essential molecular pathways that involve receptor-interacting protein kinases (RIP1/RIP3) and mixed lineage kinase domain-like protein (MLKL), which lead to membrane disruption, the release of damage-associated molecular patterns (DAMPs), and subsequent inflammation. Melatonin, recognized for its potent antioxidant and anti-inflammatory properties, has emerged as a promising therapeutic agent that can inhibit necroptosis through various mechanisms. In neurological diseases such as intracerebral hemorrhage, traumatic brain injury, and cerebral ischemia-reperfusion, melatonin suppresses necroptosis by downregulating RIP1/RIP3/MLKL signaling, upregulating A20 (TNFAIP3), and inhibiting the HMGB1/TLR4/NF-κB pathway. In lung disorders, melatonin attenuates cadmium- and LPS-induced necroptosis by modulating the Ang-II axis, reducing TNF-α-mediated signaling, and acting through MT1/MT2 receptors. In liver fibrosis models, melatonin inhibits RIP1-RIP3 necrosome formation, reduces oxidative stress, and decreases DAMPs-mediated immune responses. Similarly, in testicular toxicity induced by tetrabromobisphenol A (TBBPA), melatonin suppresses necroptosis by inhibiting the several pathways and reducing ROS overproduction. These findings highlight melatonin’s ability to modulate necroptosis across diverse tissues, offering protection against inflammation, oxidative stress, and cell death. By targeting necroptosis-related pathways, melatonin presents a versatile therapeutic strategy for treating diseases characterized by excessive cell death and inflammation, including stroke, myocardial infarction, pancreatitis, and autoimmune disorders. This review underscores the potential of melatonin as a novel intervention for necroptosis-related pathologies, emphasizing its role in restoring cellular homeostasis and mitigating tissue damage.
      datePublished:2025-06-17T00:00:00Z
      dateModified:2025-06-17T00:00:00Z
      pageStart:1
      pageEnd:13
      sameAs:https://doi.org/10.1007/s11033-025-10713-x
      keywords:
         Melatonin
         Necroptosis
         Inflammation
         Oxidative stress
         Animal Biochemistry
         Animal Anatomy / Morphology / Histology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11033-025-10713-x/MediaObjects/11033_2025_10713_Figa_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11033-025-10713-x/MediaObjects/11033_2025_10713_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs11033-025-10713-x/MediaObjects/11033_2025_10713_Fig2_HTML.png
      isPartOf:
         name:Molecular Biology Reports
         issn:
            1573-4978
            0301-4851
         volumeNumber:52
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer Netherlands
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Mohammad Sheibani
            affiliation:
                  name:Iran University of Medical Sciences
                  address:
                     name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
                     type:PostalAddress
                  type:Organization
                  name:Iran University of Medical Sciences
                  address:
                     name:Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Azam Hosseinzadeh
            affiliation:
                  name:Iran University of Medical Sciences
                  address:
                     name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Iman Fatemi
            affiliation:
                  name:Kerman University of Medical Sciences
                  address:
                     name:Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Saeed Mehrzadi
            affiliation:
                  name:Iran University of Medical Sciences
                  address:
                     name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Molecular Biology Reports
      issn:
         1573-4978
         0301-4851
      volumeNumber:52
Organization:
      name:Springer Netherlands
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Iran University of Medical Sciences
      address:
         name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
         type:PostalAddress
      name:Iran University of Medical Sciences
      address:
         name:Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
         type:PostalAddress
      name:Iran University of Medical Sciences
      address:
         name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
         type:PostalAddress
      name:Kerman University of Medical Sciences
      address:
         name:Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
         type:PostalAddress
      name:Iran University of Medical Sciences
      address:
         name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Mohammad Sheibani
      affiliation:
            name:Iran University of Medical Sciences
            address:
               name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
               type:PostalAddress
            type:Organization
            name:Iran University of Medical Sciences
            address:
               name:Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
               type:PostalAddress
            type:Organization
      name:Azam Hosseinzadeh
      affiliation:
            name:Iran University of Medical Sciences
            address:
               name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
               type:PostalAddress
            type:Organization
      name:Iman Fatemi
      affiliation:
            name:Kerman University of Medical Sciences
            address:
               name:Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
               type:PostalAddress
            type:Organization
      name:Saeed Mehrzadi
      affiliation:
            name:Iran University of Medical Sciences
            address:
               name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
      name:Department of Pharmacology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
      name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
      name:Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran
      name:Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(314)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.26s.

LINK . SPRINGER . COM {}